Protein Metrics Inc. and Bruker Daltonik GmbH today signed a formal co-marketing agreement, bringing the two companies closer together in providing scientists with a best-in-class solution for biotherapeutics characterization.
FULL PRESS RELEASE –> See the full press release here.
Protein Metrics Inc. Announces Third Year of Record Growth and Change in Leadership. See the full press release here.
Learn from Pfizer’s Michelle English how to Streamline Your Workflow for Sequence Variant Analysis with the BPI on-demand webinar.
We are excited to announce that we are hosting the first series of Regional Workshops. For more information, please visit our Workshop Information Page.
We are hosting these in Dublin, Ireland (April 6, 2016), South San Francisco, CA (April 29, 2016), and Cambridge, MA (May 16, 2016) and will be including speakers from Pfizer, Protea, Oxford Univeristy, University of Michigan, and NIBRT. We will also be providing detailed demonstrations and having discussions about best practices and advances in data analysis for biopharma. Check it out – we look forward to seeing you there.
Nature.com highlights Protein Metrics new Intact Mass software in their proteomics product focus. “Advances in Mass Spectrometry
With the advent of a wider range of therapeutic proteins, traditional methods no longer meet the requirements for speed and sensitivity. Protein Metrics Inc. has created PMI Intact Mass software, a new intact mass analysis package that enables reports from low or high-resolution mass spectrometry (MS), from any MS vendor or instrument.”
We are pleased to announce the latest release of Protein Metrics Biopharma Suite (Byonic™ v2.7, Byologic® v2.3 and Byomap™ v2.3). This release includes many, many enhancements, including:
- New report capabilities: Auto-generation of pivot tables, visulatization of results on multiple tabs, export to comprehensive PDF.
- Waters MSe files support
- Direct reading of Bruker files
- Lock mass calibration supported during project creation
- PMI-advanced centroiding as an option to vendor centroiding
- Add “File > Save Copy As” menu option
- and many additional new features based on customer requests…
With these new features, now is the perfect time to take a detailed look at how this software can impact your analyses and reporting workflows. To see these new features and to take advantage of a free-trial of this software, simply contact email@example.com.
Marshall Bern will be presenting a poster on work with Albert Heck’s Group and will be participating in the Glycoinformatics Hands-on Workshop – 2nd December 13:30 during the Glycobiology meeting in San Francisco, Dec 1- 4.
Please click on the poster below and request a reprint or submit your questions.
Protein Metrics was well represented in oral presentations at the BioProcess International 2015 meeting inteh Analytical, Formulation, and Quality Session. If you missed the talks, please email us for information.
Implementing Multi-Attribute LC/MS Methods for More Informed Process Development (Matthew Traylor, Shire)
Multi-attribute LC/MS peptide mapping provides comprehensive characterization and quantitation of protein post-translational modifications and impurities. Recent software advances have facilitated the routine application of this technology, enabling more informed decision making throughout process development. Case studies will demonstrate the implementation of multi-attribute LC/MS during different stages of development.
Characterization and Quantitative Comparison of Remicade® and its Biosimilar Remsima™ (Anna Schwendeman, Ph.D., Assistant Professor, Medicinal Chemistry, University of Michigan)
Remsima™ is a mimic of an eight billion dollar product Remicade® and the first mAb biosimilar approved in Europe and Canada. We compared multiple lots of Remsima™ and Remicade® by complete proteomic analysis of digested proteins by LC-MS coupled with powerful statistical software. Samples were quantitatively compared according to levels of oxidation, deamidation, terminal lysine truncation, glycation, glycosylation, disulfide bond formation, sequence variance and host cell proteins. Whereas the products appeared to be highly similar for most of the parameters tested, the levels of glycation was significantly higher for Remsima™ relative to Remicade®. Increased hydrophilicity in the biosimilar was confirmed by reduced retention times of IdeS digests by RP-HPLC. Increased glycation could reasonably be responsible for reduced binding to Fcgamma receptor and, potentially even, reduced efficacy in treatment of inflammatory bowel disease. Hence, the proteomic analysis described here may be useful for detailed comparative structural characterization of pharmaceutical proteins.